On September 5th, the U.S. FDA granted full approval for our medicine to slow kidney function decline in adults with IgA nephropathy. For more information, see our Press Release.
Search for information about a product, therapeutic area or event
Media, investors, advocacy organizations and others, please contact us here.
For US healthcare professionals only
The purpose of this Travere Therapeutics Medical Affairs website is to support healthcare professionals with scientific information. This website is also a channel for US healthcare professionals to submit questions or connect with Travere Therapeutics US healthcare professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US healthcare professional
DEFINE: Physicians – An International Delphi Survey to Identify Consensus in the Care of Patients with Focal Segmental Glomerulosclerosis / Idiopathic Syndrome
Humanistic Burden or Rare Kidney Diseases: Understanding the Impact of FSGS and IgAN on Patients and Caregivers Study (HONUS) Rationale and Study Design
The Dual Endothelin Angiotensin Receptor Antagonist (Deara) Sparsentan Protects from Glomerular Hypercellularity and Associated Immune/Inflammatory Gene-Network-Activity in a Modal of Iga Nephropathy (Igan)
The Dual Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) Antagonist, Sparsentan, Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy
The Dual Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) Antagonist, Sparsentan, Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy
The Dual Endothelin Type A Receptor (ETAR) and Angiotensin II Type 1 Receptor (AT1R) Antagonist, Sparsentan, Protects Against the Development of Albuminuria and Glomerulosclerosis in the gddY Mouse Model of IgA Nephropathy
Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy
PROTECT in Immunoglobulin A Nephropathy (IgAN): Study Design of a Phase 3, Randomized Double-blind, International, Active-controlled Study of the Efficacy and Safety of Sparsentan